Elaine Mardis - QIAGEN NV Independent Member of the Supervisory Board
| QIA Stock | EUR 37.14 0.29 0.79% |
Executive
Prof. Dr. Elaine R. Mardis has served as Independent Member of the Supervisory Board of Qiagen N.V. since 2014. Elaine joined the Companys Supervisory Board and its Science and Technology Committee in 2014. Since 2014 she has served on the Scientific Advisory Board of Ingenuity Systems, Inc. Dr. Mardis holds over two decades experience in DNA preparation and sequencingbased research. She is the Robert E. and Louise F. Dunn Distinguished Professor of Medicine at Washington University and also serves as CoDirector of its McDonnell Genome Institute where she has worked since 1993. Prof. Dr. Mardis serves on several study sections of the U.S. National Institutes of Health, is an editorial board member of Molecular Cancer Research, Annals of Oncology, and Disease Models and Mechanisms and acts as a reviewer for Nature and The New England Journal of Medicine. Prof. Dr. Mardis also serves on the scientific advisory boards of QIAGEN Silicon Valley and Regeneron Genomics Center. Between 2008 and 2009 she served on the board of directors of Applied Biosytems, Inc. Prof. Dr. Mardis is also Professor in the Department of Genetics, with an adjunct appointment in the Department of Molecular Microbiology at Washington University. Prior to joining the Washington since 2014.
| Age | 56 |
| Tenure | 11 years |
QIAGEN NV Leadership Team
Elected by the shareholders, the QIAGEN NV's board of directors comprises two types of representatives: QIAGEN NV inside directors who are chosen from within the company, and outside directors, selected externally and held independent of QIAGEN. The board's role is to monitor QIAGEN NV's management team and ensure that shareholders' interests are well served. QIAGEN NV's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, QIAGEN NV's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Metin Colpan, Independent Member of the Supervisory Board | ||
| Stephane Bancel, Independent Member of the Supervisory Board | ||
| Hakan Bjorklund, Independent Chairman of the Supervisory Board | ||
| Thierry Bernard, Chief Executive Officer, Senior Vice President - Molecular Diagnostics Business Area, Member of the Executive Committee | ||
| Toralf Haag, Member of the Supervisory Board | ||
| Elaine Mardis, Independent Member of the Supervisory Board | ||
| Ross Levine, Independent Member of the Supervisory Board | ||
| Thomas Ebeling, Member of the Supervisory Board | ||
| Roland Sackers, Managing Director, Chief Financial Officer, Member of the Executive Committee | ||
| Elizabeth Tallett, Independent Member of the Supervisory Board | ||
| Lawrence Rosen, Independent Chairman of the Supervisory Board |
QIAGEN Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is QIAGEN NV a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Current Valuation | 11.01 B | |||
| Price To Book | 3.38 X | |||
| Price To Sales | 5.11 X | |||
| Revenue | 2.14 B | |||
| EBITDA | 779.36 M | |||
| Net Income | 423.21 M | |||
| Total Debt | 1.47 B | |||
| Cash Flow From Operations | 715.26 M | |||
| Price To Earnings To Growth | 8.39 X | |||
| Number Of Employees | 22 |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Information and Resources on Investing in QIAGEN Stock
When determining whether QIAGEN NV offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of QIAGEN NV's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Qiagen Nv Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Qiagen Nv Stock:Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in QIAGEN NV. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. For information on how to trade QIAGEN Stock refer to our How to Trade QIAGEN Stock guide.You can also try the Portfolio Holdings module to check your current holdings and cash postion to detemine if your portfolio needs rebalancing.